Adimmune, your trusted partner to global market
We tailor our services to customers’ needs and offer solutions for various scales, phases, and timelines. We are one of the key suppliers of high-quality vaccines and biologics around the world.
View All
CDMO
Collaborative Development
Process Development
Customized Service
One-stop
Filling and Packaging Service
Regulatory Support
Market Entry
Support Resilient
Supply for Vaccines
We engage with the WHO Pandemic Influenza Preparedness Framework to foster the development and access to vaccines. Recognized by US FDA and the EU, we tackle health challenges by leveraging our high standards of quality.
.jpg)
26 Dec. 2023
Adimmune Broadens Market Reach for Flu Vaccine, Initiates New CDMO Ventures in 2024
Adimmune Corporation (TWSE: 4142) announced during the institutional investor conference today that Adimmune has submitted the application for marketing authorization of its quadrivalent influenza vaccine to Brazilian ANVISA in November, marking its official initiation for entry into the Southern Hemisphere’s influenza market. Another significant development is that Adimmune has successfully resumed production of its tetanus vaccine in Taiwan, and the supply has generated positive reception in the domestic market. The demand of tetanus vaccine is also strong in Southeast Asia and China, and Adimmune may anticipate a promising leap in export sales once the tetanus vaccine is approved in those markets. Building on its current CDMO performance, Adimmune foresees expanding partnership with bio-pharmaceutical manufacturers in Korea and France and expects to realize substantial growth in 2024.
24 Oct. 2023
Adimmune’s Tetanus Vaccine Set to Re-launce by Year’s End
Adimmune Corporation (TWSE: 4142) today announced that the Company has successfully extended the marketing authorization for its tetanus vaccine and is prepared to commence the steady supply of no less than one million doses annually for the domestic market in Taiwan as early as November 2023.
23 Aug. 2023
Epidemic Prevention in Taiwan: Adimmune Secures Advanced Purchase Agreement for Pandemic Influenza Vaccine
Adimmune Corporation (TWSE: 4142) today announced the Company has been awarded the advanced purchase agreement (APA) for pandemic influenza vaccine by Taiwan Centers for Disease Control (CDC), Ministry of Health and Welfare. This APA ensures Taiwan’s swift access to vaccines in the event of a new influenza pandemic. As the only vaccine manufacturer in Taiwan participating in the Influenza Vaccine Supply (IVS) International Task Force of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Adimmune is uniquely positioned to obtain new influenza virus strains promptly.
